Focused On-demand Library for Casein kinase I isoform gamma-1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q9HCP0

UPID:
KC1G1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9HCP0; Q5JPH1; Q96AE9; Q9HCP1

BACKGROUND:
The protein Casein kinase I isoform gamma-1, with the unique identifier Q9HCP0, functions as a serine/threonine-protein kinase. It distinguishes itself by preferentially utilizing acidic proteins such as caseins as substrates. This enzyme's ability to phosphorylate numerous proteins positions it as a significant contributor to the Wnt signaling pathway and the regulation of glutamate-mediated synaptic transmission, indicating its pivotal role in cellular signaling and neural function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Casein kinase I isoform gamma-1 offers a promising avenue for the development of novel therapeutic interventions. Given its critical involvement in essential cellular and neural processes, targeting this kinase could lead to innovative treatments for diseases where these pathways are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8323 of 8789